Cat. No.: DAB-0011693
Product Information | |
---|---|
Clonality | Monoclonal |
Isotype | IgG |
Host Species | Rabbit |
Reactivity | Human |
Applications | WB, IP |
Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gly45 of human adenosine deaminase protein. |
Format | Liquid |
Purity | Affinity purity |
Target Information | |
---|---|
Target Name | ADA |
UniProt No. | P00813 |
Gene ID | 100 |
Gene Description | Adenosine deaminase catalyzes adenosine degradation. Lack of this enzyme leads to the accumulation of toxic metabolites causing severe combined immunodeficiency, an autosomal recessive disorder. Differentiation and function of T cells, B cells, and natural killer cells are impaired in ADA-SCID patients leading to recurrent infections. Gene therapies for ADA-SCID were reported to correct the metabolic defect and restore the deficient immune function. |
Shipping & Storage | |
---|---|
Shipping | Shipped at 4 °C. |
Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.